Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA.
Hepatology. 2013 Nov;58(5):1681-92. doi: 10.1002/hep.26514. Epub 2013 Sep 17.
MicroRNA-122 (miR-122), a pivotal liver-specific miRNA, has been implicated in several liver diseases including hepatocellular carcinoma (HCC) and hepatitis C and B viral infection. This study aimed to explore epigenetic regulation of miR-122 in human HCC cells and to examine the effect of hepatitis C virus (HCV) and hepatitis B virus (HBV). We performed microRNA microarray analysis and identified miR-122 as the most up-regulated miRNA (6-fold) in human HCC cells treated with 5'aza-2'deoxycytidine (5-Aza-CdR, DNA methylation inhibitor) and 4-phenylbutyric acid (PBA, histone deacetylation inhibitor). Real-time polymerase chain reaction (PCR) analysis verified significant up-regulation of miR-122 by 5'aza and PBA in HCC cells, and to a lesser extent in primary hepatocytes. Peroxisome proliferator activated receptor-gamma (PPARγ) and retinoid X receptor alpha (RXRα) complex was found to be associated with the DR1 and DR2 consensus site in the miR-122 gene promoter which enhanced miR-122 gene transcription. 5-Aza-CdR and PBA treatment increased the association of PPARγ/RXRα, but decreased the association of its corepressors (N-CoR and SMRT), with the miR-122 DR1 and DR2 motifs. The aforementioned DNA-protein complex also contains SUV39H1, an H3K9 histone methyl transferase, which down-regulates miR-122 expression.
These findings establish a novel role of the PPARγ binding complex for epigenetic regulation of miR-122 in human HCC cells. Moreover, we show that hepatitis B virus X protein binds PPARγ and inhibits the transcription of miR-122, whereas hepatitis C viral particles exhibited no significant effect; these findings provide mechanistic insight into reduction of miR-122 in patients with HBV but not with HCV infection.
微小 RNA-122(miR-122)是一种重要的肝脏特异性 miRNA,与多种肝脏疾病有关,包括肝细胞癌(HCC)和丙型肝炎病毒(HCV)和乙型肝炎病毒(HBV)感染。本研究旨在探讨 miR-122 在人 HCC 细胞中的表观遗传调控,并研究 HCV 和 HBV 的影响。我们进行了 microRNA 微阵列分析,发现 miR-122 在经 5'aza-2'脱氧胞苷(5-Aza-CdR,DNA 甲基化抑制剂)和 4-苯丁酸(PBA,组蛋白去乙酰化抑制剂)处理的人 HCC 细胞中表达上调最明显(6 倍)。实时聚合酶链反应(PCR)分析证实,5-Aza 和 PBA 在 HCC 细胞中显著上调 miR-122 的表达,在原代肝细胞中则上调程度较低。过氧化物酶体增殖物激活受体-γ(PPARγ)和视黄酸 X 受体α(RXRα)复合物与 miR-122 基因启动子中的 DR1 和 DR2 保守位点结合,增强了 miR-122 基因的转录。5-Aza-CdR 和 PBA 处理增加了 PPARγ/RXRα 的结合,但减少了其核心抑制因子(N-CoR 和 SMRT)与 miR-122 DR1 和 DR2 基序的结合。上述 DNA-蛋白复合物还包含 SUV39H1,一种 H3K9 组蛋白甲基转移酶,下调 miR-122 的表达。
这些发现确立了 PPARγ 结合复合物在人 HCC 细胞中对 miR-122 表观遗传调控的新作用。此外,我们表明乙型肝炎病毒 X 蛋白结合 PPARγ 并抑制 miR-122 的转录,而丙型肝炎病毒颗粒则没有显著影响;这些发现为乙型肝炎病毒感染患者中 miR-122 减少提供了机制见解,但丙型肝炎病毒感染患者中则没有。